Oxler Private Wealth’s Royalty Pharma RPRX Stock Holding History

Oxler Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,570	Closed	-$615K	–	95
2022 Q4	$615K	Hold	15,570	–	–	0.33%	63
2022 Q3	$626K	Buy	+15,570	New	+$665K	0.35%	64
2022 Q2	–	Sell	-15,570	Closed	-$638K	–	70
2022 Q1	$606K	Hold	15,570	–	–	0.27%	78
2021 Q4	$620K	Buy	15,570 +9,000	+137%	+$350K	0.26%	84
2021 Q3	$237K	Hold	6,570	–	–	0.1%	120
2021 Q2	$269K	Buy	+6,570	New	+$279K	0.12%	115
2021 Q1	–	Sell	-1,250	Closed	-$62K	–	188
2020 Q4	$62K	Buy	+1,250	New	+$53K	0.03%	150

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxler Private Wealth's RPRX Position: Q1 2023 in Review

Oxler Private Wealth sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 15,570 shares — an estimated $615K sold.

Oxler Private Wealth first reported a position in RPRX in Q4 2020 and held it in 7 quarters. The position peaked at $626K in Q3 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

Oxler Private Wealth reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
Oxler Private Wealth sold 15,570 Royalty Pharma shares in Q1 2023, an estimated $615K.
Oxler Private Wealth first reported a position in Royalty Pharma in Q4 2020 and held it in 7 quarters.
Oxler Private Wealth's Royalty Pharma position peaked at $626K in Q3 2022.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Oxler Private Wealth's 13F filing for Q1 2023, filed 10 May 2023.